Leadership Team
Meet our experienced team.
Watch Abzena’s Senior Director, Bioassay, Erika Kovacs as she explores key considerations when developing stage-appropriate bioassays for complex biologics and bioconjugates, to accelerate and de-risk the development process to IND. Using case studies, she will provide insights into topics including selecting to right assay depending on development stage and MoA, overall application of developability for lead candidate selection, and requirements for GMP potency testing.
Progressing a new biologic or bioconjugate forward from discovery to IND can be a challenging process, especially considering the increasingly complex therapies being developed today. Having powerful and reliable bioassays throughout your development journey is key for generating a comprehensive data package that will allow you to make the best decisions, maximizing the likelihood of progressing a successful drug to the clinic. Like many processes during drug development, assay design and execution is a balancing act, ensuring that your bioassay resembles the desired pharmacology as closely as possible, while minimally compromising on sensitivity, robustness, accuracy and precision, is essential to the success of your program.